Vevo
Daniele Merico is a highly experienced professional in the fields of computational biology and bioinformatics, currently serving as Chief Data Officer and VP of Computational Biology at Vevo Therapeutics since January 2023. Daniele has held various prestigious positions, including Associate Investigator and Visiting Scientist at The Hospital for Sick Children, and has extensive leadership experience at Deep Genomics, where roles included Vice President and Head of Target Identification. With a strong academic background, including a Ph.D. in Molecular and Cellular Biology from Università degli Studi di Milano, Daniele has contributed significantly to the identification of causal variants for Mendelian disorders and the development of bioinformatics analysis pipelines. Daniele's multidisciplinary expertise spans genomics, molecular diagnostics, and therapeutic program development, influencing strategic decisions in multiple organizations throughout a distinguished career.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.